SecBot SecBot
SECBOTREPLAY Home › Report › EVAX

EVAX · Evaxion announced a poster presentation at the International…

Evaxion · PRESS-RELEASE filed Jul 1, 2026 at 08:00 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Jul 1, 2026 at 08:00 ET

Evaxion announced a poster presentation at the International Herpesvirus Workshop 2026 for its preclinical CMV vaccine candidate EVX-V1. The data will guide final antigen selection for this next-generation candidate, but this is an early-stage, non-clinical event with no financial terms, regulatory action, or near-term value inflection, simply a routine scientific conference disclosure for a preclinical program.

  • Poster presentation of new preclinical data for EVX-V1 at IHW 2026 in Montreal on July 12, 2026.
  • EVX-V1 is a multi-component CMV vaccine candidate combining AI-discovered antigens with AI-optimized gB antigen.
  • The data will guide final antigen selection for the vaccine candidate, no clinical timeline or regulatory milestone announced.
  • No CMV vaccine has been approved to date; Evaxion remains at the preclinical stage for this program.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access